Kineta Price to Free Cash Flow Ratio 2014-2024 | KANT
Historical price to free cash flow ratio values for Kineta (KANT) since 2014.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Kineta Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-09-18 |
0.57 |
|
0.00 |
| 2024-06-30 |
0.53 |
$-0.67 |
0.00 |
| 2024-03-31 |
0.53 |
$-1.23 |
0.00 |
| 2023-12-31 |
3.63 |
$-1.44 |
0.00 |
| 2023-09-30 |
3.40 |
$-2.51 |
0.00 |
| 2023-06-30 |
2.58 |
$-3.27 |
0.00 |
| 2023-03-31 |
3.31 |
$-3.26 |
0.00 |
| 2022-12-31 |
6.35 |
$-3.86 |
0.00 |
| 2022-09-30 |
1.57 |
$20.90 |
0.08 |
| 2022-06-30 |
1.82 |
$16.10 |
0.11 |
| 2022-03-31 |
1.50 |
$10.05 |
0.15 |
| 2021-12-31 |
2.96 |
$-4.10 |
0.00 |
| 2021-09-30 |
10.32 |
$-60.19 |
0.00 |
| 2021-06-30 |
11.65 |
$-29.04 |
0.00 |
| 2021-03-31 |
18.10 |
$-41.81 |
0.00 |
| 2020-12-31 |
17.00 |
$-54.02 |
0.00 |
| 2020-09-30 |
22.00 |
$1.02 |
21.52 |
| 2020-06-30 |
27.40 |
$-53.69 |
0.00 |
| 2020-03-31 |
22.80 |
$-82.45 |
0.00 |
| 2019-12-31 |
45.60 |
$-91.83 |
0.00 |
| 2019-09-30 |
16.90 |
$-177.27 |
0.00 |
| 2019-06-30 |
19.52 |
$-202.30 |
0.00 |
| 2019-03-31 |
25.20 |
$-203.49 |
0.00 |
| 2018-12-31 |
64.80 |
$-215.45 |
0.00 |
| 2018-09-30 |
48.20 |
$-214.62 |
0.00 |
| 2018-06-30 |
55.80 |
$-232.12 |
0.00 |
| 2018-03-31 |
95.00 |
$-252.23 |
0.00 |
| 2017-12-31 |
116.60 |
$-289.26 |
0.00 |
| 2017-09-30 |
42.00 |
$-347.17 |
0.00 |
| 2017-06-30 |
93.60 |
$-358.40 |
0.00 |
| 2017-03-31 |
156.40 |
$-290.84 |
0.00 |
| 2016-12-31 |
245.20 |
$-314.41 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
